nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0317	0.0317	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0297	0.0297	CbGpPWpGaD
Apraclonidine—ADRA2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0271	0.0271	CbGpPWpGaD
Apraclonidine—ADRA2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0263	0.0263	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0259	0.0259	CbGpPWpGaD
Apraclonidine—ADRA2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0253	0.0253	CbGpPWpGaD
Apraclonidine—ADRA2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0245	0.0245	CbGpPWpGaD
Apraclonidine—ADRA2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0245	0.0245	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0241	0.0241	CbGpPWpGaD
Apraclonidine—ADRA2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0229	0.0229	CbGpPWpGaD
Apraclonidine—ADRA2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0228	0.0228	CbGpPWpGaD
Apraclonidine—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0221	0.0221	CbGpPWpGaD
Apraclonidine—ADRA2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0221	0.0221	CbGpPWpGaD
Apraclonidine—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0215	0.0215	CbGpPWpGaD
Apraclonidine—ADRA2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0213	0.0213	CbGpPWpGaD
Apraclonidine—ADRA2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0206	0.0206	CbGpPWpGaD
Apraclonidine—ADRA2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0206	0.0206	CbGpPWpGaD
Apraclonidine—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0205	0.0205	CbGpPWpGaD
Apraclonidine—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.02	0.02	CbGpPWpGaD
Apraclonidine—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0199	0.0199	CbGpPWpGaD
Apraclonidine—ADRA2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0192	0.0192	CbGpPWpGaD
Apraclonidine—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0186	0.0186	CbGpPWpGaD
Apraclonidine—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0186	0.0186	CbGpPWpGaD
Apraclonidine—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.018	0.018	CbGpPWpGaD
Apraclonidine—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0173	0.0173	CbGpPWpGaD
Apraclonidine—ADRA2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0171	0.0171	CbGpPWpGaD
Apraclonidine—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0168	0.0168	CbGpPWpGaD
Apraclonidine—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0168	0.0168	CbGpPWpGaD
Apraclonidine—ADRA2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.016	0.016	CbGpPWpGaD
Apraclonidine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0156	0.0156	CbGpPWpGaD
Apraclonidine—ADRA2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0144	0.0144	CbGpPWpGaD
Apraclonidine—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.014	0.014	CbGpPWpGaD
Apraclonidine—ADRA2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0135	0.0135	CbGpPWpGaD
Apraclonidine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.013	0.013	CbGpPWpGaD
Apraclonidine—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0118	0.0118	CbGpPWpGaD
Apraclonidine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0109	0.0109	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00563	0.00563	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00547	0.00547	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00526	0.00526	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00522	0.00522	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.0051	0.0051	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00509	0.00509	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00507	0.00507	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00488	0.00488	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00476	0.00476	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00474	0.00474	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00472	0.00472	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00448	0.00448	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00441	0.00441	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00435	0.00435	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00427	0.00427	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00427	0.00427	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00418	0.00418	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00415	0.00415	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00414	0.00414	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00406	0.00406	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00405	0.00405	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00396	0.00396	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00386	0.00386	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00386	0.00386	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00385	0.00385	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00378	0.00378	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00365	0.00365	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00358	0.00358	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00355	0.00355	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.0035	0.0035	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00341	0.00341	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0034	0.0034	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00331	0.00331	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00331	0.00331	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00331	0.00331	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0033	0.0033	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00318	0.00318	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00313	0.00313	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00309	0.00309	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00309	0.00309	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00308	0.00308	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00307	0.00307	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.00305	0.00305	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00288	0.00288	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00284	0.00284	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00278	0.00278	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0027	0.0027	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0027	0.0027	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00265	0.00265	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00259	0.00259	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00252	0.00252	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00251	0.00251	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00251	0.00251	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.00248	0.00248	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00234	0.00234	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00232	0.00232	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00216	0.00216	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00215	0.00215	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00202	0.00202	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00193	0.00193	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00187	0.00187	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0018	0.0018	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00176	0.00176	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00175	0.00175	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00175	0.00175	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00174	0.00174	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0017	0.0017	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00164	0.00164	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00163	0.00163	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00163	0.00163	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00159	0.00159	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00158	0.00158	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00157	0.00157	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00153	0.00153	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00148	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00146	0.00146	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00143	0.00143	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00142	0.00142	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00142	0.00142	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00139	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00133	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00132	0.00132	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00129	0.00129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00129	0.00129	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00122	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0012	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00114	0.00114	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00111	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00103	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00103	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.001	0.001	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000996	0.000996	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000965	0.000965	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000937	0.000937	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000934	0.000934	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000926	0.000926	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000905	0.000905	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000873	0.000873	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000844	0.000844	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000841	0.000841	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000819	0.000819	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000784	0.000784	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000763	0.000763	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000761	0.000761	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000709	0.000709	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000654	0.000654	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000611	0.000611	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000534	0.000534	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000497	0.000497	CbGpPWpGaD
